F13A1 is widely regarded as a cancer-related gene and FDA-approved drug target that is involved in lung cancer [27, 28], oral squamous cell carcinoma [29], and colorectal cancer [30], consistent with our results. This evidence concerns the gene F13A1 and cancer.